Ache Sugar Free Launch

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Aché launches new sugar free version of Inellare

Oxford Pharmascience (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, confirms that its partner in Brazil, Aché Pharmaceuticos (Aché) has launched a new sugar free version of its calcium and vitamin D chew marketed under the brand name Inellare.

Nigel Theobald, CEO of Oxford Pharmascience commented

"Our relationship with Aché continues to grow from strength to strength and Aché's association with and seal of approval from ANAD (National Association of Diabetes Care) shows how seriously they are marketing our product. We could not hope for a better partner in Brazil"

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

N+1 Singer

Shaun Dobson/Jenny Wyllie +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.